Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

NB-4746

Source date not recordedAnalyse record ↗

Clinical-stage SARM1 inhibitor intended to preserve axons by blocking injury-triggered NAD breakdown in amyotrophic lateral sclerosis.

Modality
oral brain-penetrant reversible orthosteric small-molecule SARM1 inhibitor
Availability (US)
Phase 1b/2 ALS study Recruiting; first patient dosing announced June 2026
Biomarkers
treatment-emergent adverse events; neurofilament light; plasma and cerebrospinal-fluid exposure; SARM1 pathway engagement
Hallmark targeted
mitochondrial dysfunction, NAD+ depletion, loss of proteostasis, neuronal degeneration
Kind
investigational drug
Clinical trials
NCT07369076 / EU CT 2025-523939-18-00 — Phase 1b/2 study in amyotrophic lateral sclerosis